Does Anti-Mullerian Hormone Level Change During recFSH Treatment?

Authors : Yetkin Karasu, Berna Dilbaz, Berfu Demir, Serdar Dilbaz

Pages : 136-141

View : 28 | Download : 10

Publication Date : 2017-12-01

Article Type : Research Paper

Abstract :The aim of this study to compare intracycle variability of Anti-Mullerian Hormone (AMH) in women with Polycystic Ovary Syndrome (PCOS) and normoresponder infertile patients during controlled ovarian hyper stimulation (COH) with follicle stimulating hormone (FSH). Infertile PCOS (n=30) patients were grouped into two and 15 patients were treated with long luteal gonodotropin releasing hormone analogue (GnRHa) and intracytoplasmic sperm injection (ICSI) and 15 PCOS patients were treated with COH-intrauterine insemination (IUI). Non-PCOS (n=30) patients were treated with COH-IUI. AMH was measured three times in all groups throughout the cycle (basal, mid-cycle, luteal). Intracycle variations of serum AMH levels in PCOS and non-PCOS patients underwent different amount of exogenous FSH treatment were compared. Pregnancy rates were also compared.   AMH levels in the PCOS patients were 2-2.5 times higher than non-PCOS patients. Total gonodotropin dose used was higher in the PCOS patients (p<0.001). Intracycle AMH variability throughout the cycle wasn’t significant in PCOS patients but in non-PCOS patients declining AMH levels were observed (p=0.039). Our findings confirm that AMH levels were higher, remain steady and unaffected by high doses of FSH treatment in PCOS patients. On the other hand in non-PCOS patients there was a small decline in AMH levels with FSH. Clinical pregnancy rates were similar.
Keywords : Polycystic Ovary Syndrome, Anti Mullerian Hormone, In Vitro Fertilization